drugset / Trial / NCT00681629
Schizophrenic Patients in Integrated Care
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a period of 18 month
Timeline
- Start
- 2008-07
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Quetiapine | Small molecule | 400 mg | Oral |
| Background | Quetiapine | Small molecule | 500 mg | Oral |
| Background | Quetiapine | Small molecule | 600 mg | Oral |
| Background | Quetiapine | Small molecule | 700 mg | Oral |
| Background | Quetiapine | Small molecule | 800 mg | Oral |